BCI
CRNX

Brinker Capital Investments’s Crinetics Pharmaceuticals CRNX Stock Holding History

Brinker Capital Investments’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.4M Buy
37,526
+27
+0.1% +$1K 0.01% 983
2026
Q1 		$1.36M Buy
37,499
+7,004
+23% +$313K 0.01% 948
2025
Q4 		$1.42M Buy
30,495
+13,633
+81% +$607K 0.01% 1038
2025
Q3 		$702K Sell
16,862
-4
-0% -$128 0.01% 1392
2025
Q2 		$485K Sell
16,866
-814
-5% -$25.1K ﹤0.01% 1519
2025
Q1 		$593K Buy
17,680
+959
+6% +$35.8K 0.01% 1336
2024
Q4 		$855K Sell
16,721
-1,515
-8% -$84.8K 0.01% 1130
2024
Q3 		$932K Sell
18,236
-790
-4% -$40.7K 0.01% 1077
2024
Q2 		$852K Buy
19,026
+3,467
+22% +$160K 0.01% 1055
2024
Q1 		$728K Buy
+15,559
New +$609K 0.01% 1123

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brinker Capital Investments's CRNX Position: Q2 2026 in Review

Brinker Capital Investments increased its Crinetics Pharmaceuticals (CRNX) stake by 0.07% in Q2 2026, buying an estimated $1K and bringing the position to 37,526 shares worth $1.4M. The position accounts for 0.01% of the portfolio, ranked #983.

Brinker Capital Investments first reported a position in CRNX in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.42M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Brinker Capital Investments held 37,526 shares of Crinetics Pharmaceuticals worth $1.4M as of Q2 2026.
  • Brinker Capital Investments bought 27 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1K.
  • Crinetics Pharmaceuticals made up 0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #983 holding.
  • Brinker Capital Investments first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Brinker Capital Investments's Crinetics Pharmaceuticals position peaked at $1.42M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.